AI Terminal
Xspray Pharma
Declaration of Voting Results & Voting Rights Announcements • Nov 30, 2021
3129_rns_2021-11-30_8822cdd7-70c3-41ef-8348-f833d01054a5.pdf
Declaration of Voting Results & Voting Rights Announcements
Open in ViewerOpens in native device viewer
Number of shares and votes in Xspray Pharma
Xspray Pharma AB (Nasdaq Stockholm: XSPRAY) announces today that the number of shares and votes in Xspray Pharma AB has changed as a result of shares being registered due to the directed share issue which was carried out in November 2021.
Through the direct share issue, carried out in November 2021, the number of outstanding shares and votes has increased by 1,612,904, from 19,067,504 to 20,680,408. The share capital has increased by SEK 1,612,904, from SEK 19,067,504 to SEK 20,680,408.
For further information, please contact:
Per Andersson, CEO, Xspray Pharma AB Phone: +46 (0) 706 88 23 48 E-mail: [email protected]
About Xspray Pharma
Xspray Pharma AB (publ) is a pharmaceutical company with several product candidates in clinical development. Xspray Pharma uses its innovative, patented RightSize™ technology to develop improved versions of marketed drugs, primarily protein kinase inhibitors (PKIs) for the treatment of cancer. The segment is the second largest in oncology, and drug prices are very high.
The company´s innovative technology allows Xspray Pharma to gain entry as the first competitor to today's original drugs before the secondary patents expire. Xspray's goal is to become the leader in the development of improved drugs or generic versions of PKIs already marketed for the treatment of cancer, which numbered to 68 in the beginning of 2021. The company's leading product candidates, HyNap-Dasa, HyNap-Nilo, and HyNap-Sora, are stable amorphous versions of the three blockbuster cancer drugs Sprycel® (dasatinib), Tasigna® (nilotinib) and Nexavar® (sorafenib). HyNap-Dasa is being developed as an improved version of Sprycel. HyNap-Nilo is being developed as an improved version of Tasigna and has has received orphan drug status from the US FDA. HyNap-Sora is being developed as an improved version of Nexavar®.
The company has patented manufacturing technology, equipment, and the resulting products. The shares in Xspray Pharma are traded on Nasdaq Stockholm (Nasdaq Stockholm: XSPRAY). www.xspraypharma.com
This information is information that Xspray Pharma AB is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2021- 11-30 09:15 CET.
